Jose Luis Piñana1,2, Aliénor Xhaard3, Gloria Tridello4, Jakob Passweg5, Anne Kozijn6, Nicola Polverelli7, Inmaculada Heras8, Ariadna Perez9, Jaime Sanz1,2, Dagmar Berghuis10, Lourdes Vázquez11, María Suárez-Lledó12, Maija Itäla-Remes13, Tulay Ozcelik14, Isabel Iturrate Basarán15, Musa Karakukcu16, Mohsen Al Zahrani17, Goda Choi18, Marián Angeles Cuesta Casas19, Montserrat Batlle Massana20, Amato Viviana21, Nicole Blijlevens22, Arnold Ganser23, Baris Kuskonmaz24, Hélène Labussière-Wallet25, Peter J Shaw26, Zeynep Arzu Yegin27, Marta González-Vicent28, Vanderson Rocha29, Alina Ferster30, Nina Knelange3, David Navarro8, Malgorzata Mikulska31, Rafael de la Camara15, Jan Styczynski32. 1. Hematology Division, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 2. CIBERONC, Instituto Carlos III, Madrid, Spain. 3. Service d'Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France. 4. Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy. 5. University Hospital Basel, Basel, Switzerland. 6. European Society for Blood and Marrow Transplantation Data Office Leiden, Leiden, The Netherlands. 7. Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy. 8. Hematology Division, Hospital Morales Meseguer, Murcia, Spain. 9. Hematology Division, Hospital Clínico de Valencia, Valencia, Spain. 10. Willem Alexander Children's Hospital/Leiden University Medical Center, Leiden, The Netherlands. 11. Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain. 12. Hematology Division, Hospital Clínic, Barcelona, Spain. 13. Turku University Hospital, Turku, Finland. 14. Demiroglu Bilim University, Istanbul, Turkey. 15. Hematology Division, Hospital de la Princesa, Madrid, Spain. 16. Erciyes University, Faculty of Medicine, Erciyes Pediatric Bone Marrow Transplant Center, Kayseri, Turkey. 17. King Abdulaziz Medical City, Riyadh, Saudi Arabia. 18. University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 19. Hematology Division, Hospital Regional de Málaga, Malaga, Spain. 20. Hematology Division, Instituto Catalan de Oncologia-Hospital Germans Trias i Pujol, Barcelona, Spain. 21. Universita Cattolica S. Cuore, Rome, Italy. 22. Radboud University Medical Center, Nijmegen, The Netherlands. 23. Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation. Hannover Medical School, Hannover, Germany. 24. Hacettepe University Children's Hospital, Ankara, Turkey. 25. Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France. 26. Children's Hospital at Westmead, Sydney, Australia. 27. Gazi University Faculty of Medicine, Ankara, Turkey. 28. Pediatric Division, Niño Jesus Children's Hospital, Madrid, Spain. 29. Hospital Sirio-Libanes, São Paulo, Brazil. 30. Children's University Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium. 31. University of Genoa (Dipartimento di Scienze della Salute) and Istituto Nazionale per la Ricerca sul Cancro Ospedale Policlinico San Martino, Genova, Italy. 32. Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun Uniwersytet Mikołaja Kopernika, University Hospital, Bydgoszcz, Poland.
Abstract
BACKGROUND: Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). METHODS: This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. RESULTS: We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range, 0.3-73.8 years). HCoV episodes were diagnosed at a median of 222 days after transplantation. The most common HCoV subtype was OC43 (n = 170 [38%]). LRTD involvement occurred in 121 episodes (27%). HCoV infection frequently required hospitalization (18%), oxygen administration (13%), and intensive care unit (ICU) admission (3%). Three-month overall mortality after HCoV detection was 7% in the whole cohort and 16% in those with LRTD. We identified 3 conditions associated with higher mortality in recipients with LRTD: absolute lymphocyte count <0.1 × 109/mL, corticosteroid use, and ICU admission (hazard ratios: 10.8, 4.68, and 8.22, respectively; P < .01). CONCLUSIONS: Seasonal HCoV after allo-HSCT may involve LRTD in many instances, leading to a significant morbidity.
BACKGROUND: Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). METHODS: This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. RESULTS: We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range, 0.3-73.8 years). HCoV episodes were diagnosed at a median of 222 days after transplantation. The most common HCoV subtype was OC43 (n = 170 [38%]). LRTD involvement occurred in 121 episodes (27%). HCoV infection frequently required hospitalization (18%), oxygen administration (13%), and intensive care unit (ICU) admission (3%). Three-month overall mortality after HCoV detection was 7% in the whole cohort and 16% in those with LRTD. We identified 3 conditions associated with higher mortality in recipients with LRTD: absolute lymphocyte count <0.1 × 109/mL, corticosteroid use, and ICU admission (hazard ratios: 10.8, 4.68, and 8.22, respectively; P < .01). CONCLUSIONS: Seasonal HCoV after allo-HSCT may involve LRTD in many instances, leading to a significant morbidity.
Authors: Jason T Ladner; Sierra N Henson; Annalee S Boyle; Anna L Engelbrektson; Zane W Fink; Fatima Rahee; Jonathan D'ambrozio; Kurt E Schaecher; Mars Stone; Wenjuan Dong; Sanjeet Dadwal; Jianhua Yu; Michael A Caligiuri; Piotr Cieplak; Magnar Bjørås; Mona H Fenstad; Svein A Nordbø; Denis E Kainov; Norihito Muranaka; Mark S Chee; Sergey A Shiryaev; John A Altin Journal: Cell Rep Med Date: 2021-01-19
Authors: Chikara Ogimi; Hu Xie; Alpana Waghmare; Keith R Jerome; Wendy M Leisenring; Masumi Ueda Oshima; Paul A Carpenter; Janet A Englund; Michael Boeckh Journal: Bone Marrow Transplant Date: 2022-02-16 Impact factor: 5.174
Authors: Judith Schaffrath; Christina Brummer; Daniel Wolff; Udo Holtick; Nicolaus Kröger; Martin Bornhäuser; Sabrina Kraus; Inken Hilgendorf; Igor-Wolfgang Blau; Olaf Penack; Christoph Wittke; Normann Steiner; David Nachbaur; Lorenz Thurner; Heidrun Hindahl; Robert Zeiser; Claus-Philipp Maier; Wolfgang Bethge; Lutz P Müller Journal: Transplant Cell Ther Date: 2022-03-13
Authors: Jim Boonyaratanakornkit; Anton M Sholukh; Matthew Gray; Emily L Bossard; Emily S Ford; Kizzmekia S Corbett; Lawrence Corey; Justin J Taylor Journal: Viruses Date: 2021-10-14 Impact factor: 5.048